A study in the journal Clinical Infectious Diseases described how an Australian correctional facility provided unrestricted access to direct-acting antiviral therapy for hepatitis C infections among inmates. The rate of sustained virologic suppression among patients with evaluable outcomes was 97%.
A predictive score called the BE3A score that considers five factors was able to identify which patients with hepatitis C and decompensated cirrhosis would benefit the most from direct-acting antiviral therapy, Beth Israel Deaconess Medical Center researchers reported in the journal Gastroenterology. "We identified that over 30% of individuals were able to not only get rid of the virus ... but also had an improvement in liver function. They improved to the point that they no longer had liver failure," said study author Dr. Michael Curry.
Shire, Microsoft and patient organization Eurordis have formed the Global Commission to End the Diagnostic Odyssey for Children, which seeks to improve the capabilities of clinicians in diagnosing and treating rare pediatric diseases. Over 50% of rare diseases are pediatric disorders.
The sale of 7 million shares priced at $17 raised $119 million for GlycoMimetics. The firm is scheduled to launch a late-stage study in the third quarter of this year for its lead candidate GMI-1271, an E selectin antagonist, as a treatment for acute myelogenous leukemia.
Corneal transplants were performed by the Khyber Teaching Hospital in Pakistan free of charge for 95 patients. The transplants were conducted with support from the Association of Physicians of Pakistani Descent of North America and the Sri Lanka Pakistan Friendship Association.
Health Minister Ricardo Barros said Brazil's yellow fever vaccination campaign will be expanded to cover all 27 of the country's states, with the aim of reaching almost 78 million people by next year. Since July, 920 confirmed cases have been reported, compared with 610 cases during the same period a year ago.
A private placement for 2.6 million new shares has brought in $28.8 million for Kiadis Pharma. The money will be used for the development of Kiadis' T-cell immunotherapy product to curtail graft-versus-host disease in patients who have undergone hematopoietic stem cell transplants and will also support other company endeavors.
Researchers found that the use of galinpepimut-S is safe and effective in patients with high-risk multiple myeloma, according to data presented at the 44th Annual European Society for Blood and Marrow Transplantation. The findings also showed that clinical activity was associated with antigen-specific immune responses based on results of testing with 19 multiple myeloma patients with high-risk cytogenesis at diagnosis.
- Page 1